Novartis AG (NVS)
153.79
-0.86
(-0.56%)
USD |
NYSE |
Aug 28, 16:00
153.79
0.00 (0.00%)
After-Hours: 20:00
Novartis Cash from Operations (Quarterly) : 5.888B for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 5.888B |
| March 31, 2026 | 3.691B |
| December 31, 2025 | 2.254B |
| September 30, 2025 | 6.574B |
| June 30, 2025 | 6.769B |
| March 31, 2025 | 3.645B |
| December 31, 2024 | 4.193B |
| September 30, 2024 | 6.286B |
| June 30, 2024 | 4.875B |
| March 31, 2024 | 2.265B |
| December 31, 2023 | 2.547B |
| September 30, 2023 | 5.378B |
| June 30, 2023 | 3.576B |
| March 31, 2023 | 2.964B |
| December 31, 2022 | 4.132B |
| September 30, 2022 | 4.728B |
| June 30, 2022 | 3.755B |
| March 31, 2022 | 1.649B |
| December 31, 2021 | 3.884B |
| September 30, 2021 | 4.925B |
| June 30, 2021 | 4.132B |
| March 31, 2021 | 2.13B |
| December 31, 2020 | 4.086B |
| September 30, 2020 | 3.156B |
| June 30, 2020 | 3.961B |
| Date | Value |
|---|---|
| March 31, 2020 | 2.528B |
| December 31, 2019 | 3.54B |
| September 30, 2019 | 4.562B |
| June 30, 2019 | 3.111B |
| March 31, 2019 | 2.412B |
| December 31, 2018 | 3.750B |
| September 30, 2018 | 4.089B |
| June 30, 2018 | 3.940B |
| March 31, 2018 | 2.525B |
| December 31, 2017 | 3.437B |
| September 30, 2017 | 3.586B |
| June 30, 2017 | 3.582B |
| March 31, 2017 | 2.045B |
| December 31, 2016 | 3.591B |
| September 30, 2016 | 3.231B |
| June 30, 2016 | 3.111B |
| March 31, 2016 | 1.542B |
| December 31, 2015 | 4.157B |
| September 30, 2015 | 3.126B |
| June 30, 2015 | 2.91B |
| March 31, 2015 | 1.704B |
| December 31, 2014 | 5.205B |
| September 30, 2014 | 3.932B |
| June 30, 2014 | 3.384B |
| March 31, 2014 | 1.376B |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Roche Holding AG | -- |
| AstraZeneca PLC | 3.420B |
| Johnson & Johnson | 8.616B |
| Eli Lilly & Co. | 10.69B |
| Merck & Co., Inc. | 5.37B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -3.090B |
| Cash from Financing (Quarterly) | -2.031B |
| Free Cash Flow | 14.99B |
| Free Cash Flow Per Share (Quarterly) | 2.680 |
| Free Cash Flow to Equity (Quarterly) | 3.114B |
| Free Cash Flow to Firm (Quarterly) | 5.483B |
| Free Cash Flow Yield | 5.06% |